ligands acting on targets

(R)-BRD3731 is a GSK3 inhibitor extracted from patent US20160375006A1, compound example 273, has IC 50 s of 1.05 and 6.7 μM for GSK3β and GSK3α , respectivelyForm:SolidIC50&amp: Target:GSK3β 1.05 μM (IC 50 ) GSK3α 6.7 μM (IC 50 ).

(R)-BRD3731 is a GSK3 inhibitor extracted from patent US20160375006A1, compound example 273, has IC 50 s of 1.05 and 6.7 μM for GSK3β and GSK3α , respectivelyForm:SolidIC50&amp: Target:GSK3β 1.05 μM (IC 50 ) GSK3α 6.7 μM (IC 50 ).

(R)-BRD3731 is a GSK3 inhibitor extracted from patent US20160375006A1, compound example 273, has IC 50 s of 1.05 and 6.7 μM for GSK3β and GSK3α , respectivelyIC50&amp: Target:GSK3β 1.05 μM (IC 50 ) GSK3α 6.7 μM (IC 50 ).

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.

(R)-Butibufen.

(R)-Carisbamate.

(R)-Carisbamate β-D-O-Glucuronide.

(R)-Carprofen is the R-enantiomer of the antiinflammatory drug Carprofen (C184350).

(R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)Form:SolidIC50&amp: Target:β/α-1 adrenergic receptor.

(R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)Form:SolidIC50&amp: Target:β/α-1 adrenergic receptor.